Diabetes Icon in white

Diabetes

Explore facts and recommendations for pharmacological treatments for diabetes.

pharmacotherapies
Filters

We are still gathering material for this library.

Please check again soon.

We're sorry

We didn't find any resources that match your selection.

Please adjust your filter(s) and try again.

pharmacotherapies
 
Preview
Diabetes PDF

ADA Standards of Medical Care in Diabetes – 2024

Algorithms and updates from the 2024 guidelines.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
Type 1 Diabetes PDF

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Type 1 Diabetes

Summary of prescribing information and clinical trial experience regarding Novo Nordisk GLP-1 RAs and type 1 diabetes.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

GLP-1 RA Mechanism of Action (IME Content)

Visual review of GLP-1 RA's mechanism of action.

This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with permission for educational and informational purposes only and is not certified for continuing education credits.

Continue
Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes PDF

Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database

Manuscript summarizing results from a retrospective cohort study evaluating healthcare resource utilization, costs, and glycated hemoglobin levels in adult patients with T2D after discontinuing liraglutide therapy.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes Website

GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice

Manuscript exploring T2D management with emphasis on cardiovascular risk and CVOTs performed to date. Additionally includes clinical experience with GLP-1RAs for managing hyperglycemia and their impact on cardiovascular risk.

Visit site
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Diabetes Website

ADA Standards of Medical Care in Diabetes 2024: Algorithm for intensifying to injectable therapies (Poster)

Treatment algorithm of the 2024 American Diabetes Association (ADA) Standards of Medical Care in Diabetes referencing Figure 9.4 on selecting injectable therapy for patients with Type 2 Diabetes.

Visit site
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes PDF

ADA Standards of Medical Care in Diabetes 2024: Use of glucose-lowering medications in the management of T2D (Poster)

An infographic of the 2024 American Diabetes Association (ADA) Standards of Medical Care in Diabetes referencing Figure 9.3 on the use of glucose lowering medications in the management of Type 2 Diabetes.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes PDF

The Unmet Needs for Insulin Requiring Patients (Poster)

Explains barriers to daily insulin therapy and the benefit of a once-weekly dosing approach.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes PDF

Cardiovascular Risk Reduction and Primary Prevention Recommendations (Poster)

A review of the 2020 ACC Expert Consensus Pathway and 2021 AHA/ASA guidelines for the prevention of stroke. Also includes patient and clinician considerations for initiating drug therapy with demonstrated CV benefit.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes PDF

GLP-1 RAs and Cardiovascular Outcomes Trials (Poster)

A summary of key CV outcomes of GLP-1RAs on MACE endpoints and CV risk factors. Also highlights the possible mechanism of CV benefits and considerations for drug initiation and monitoring

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
Type 2 Diabetes PDF

ADA/KDIGO Consensus Report - 2022 (Poster)

Treatment algorithm for selecting glucose-lowering medication for patients with type 2 diabetes and chronic kidney disease.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Semaglutide Injection Mechanism of Action

This video discusses the mechanism of action and mechanism of protraction of the semaglutide injection.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide Mechanism of Action

This video discusses the mechanism of action of oral semaglutide.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide Mechanism of Absorption

This video discusses the mechanism of absorption of oral semaglutide.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Pharmacokinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for Oral Semaglutide

This video describes PK/PD considerations that can impact the dosing of oral semaglutide.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Drug Interactions With Oral Semaglutide

This video reviews potential drug-drug interactions with oral semaglutide.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide vs. Placebo in Drug-Naïve Adults (PIONEER 1 Study)

This video discusses the trial-design and outcomes of the PIONEER 1 study. PIONEER 1 was a 26-week, phase 3a, randomized, double-blind, parallel group, multinational trial in 703 adult patients with type 2 diabetes managed with diet and exercise alone.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)

This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide vs. Sitagliptin 100 mg (PIONEER 3 Study)

This video discusses the trial-design and outcomes of the PIONEER 3 study. PIONEER 3 was a 78-week, phase 3a, randomized, double-blind, double-dummy, multinational trial enrolling 1864 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide 14 mg vs. Liraglutide 1.8 mg vs. Placebo (PIONEER 4 Study)

This video discusses the trial-design and outcomes of the PIONEER 4 study. PIONEER 4 was a 52-week, phase 3a, randomized, double-blind, double-dummy, active- and placebo-controlled, multinational trial in 711 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)

This video discusses the trial-design and outcomes of the PIONEER 5 study. PIONEER 5 was a 26-week, phase 3a, randomized, double-blind, multinational trial enrolling 324 adults with type 2 diabetes and moderate renal impairment.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Cardiovascular Safety of Oral Semaglutide vs. Placebo (PIONEER 6 Study)

This video discusses the trial-design and outcomes of the PIONEER 6 study. PIONEER 6 was a phase 3a, randomized, double-blind, multinational trial that enrolled 3183 adult patients (age ≥50 years) with type 2 diabetes. Eligible patients were at least 50 years of age with established cardiovascular (CV) disease or chronic kidney disease, or patients were at least 60 years of age with at least one CV risk factor.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Flexible Dosing of Oral Semaglutide vs. Sitagliptin 100 mg (PIONEER 7 Study)

This video discusses the trial-design and outcomes of the PIONEER 7 study. PIONEER 7 was a 52-week, phase 3a, randomized, open-label, multinational trial with a 52-week extension enrolling 504 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Type 2 Diabetes Video

Oral Semaglutide vs. Placebo as Add-on to Insulin (PIONEER 8 Study)

This video discusses the trial-design and outcomes of the PIONEER 8 study. PIONEER 8 was a 52-week, phase 3a, randomized, double-blind, parallel-group, multinational trial enrolling 731 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
continuing education icon

Continuing Education

Find accredited opportunities in diabetes education.

Explore CE Activities

Diabetes

disease education
View Resources

Diabetes

congress materials
View Resources

Looking for additional resources?
Explore other libraries or search the Exchange.

Novo Nordisk® Scientific Exchange logo

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with permission for educational and informational purposes only and is not certified for continuing education credits.

Continue

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

Continue

GATED INTERSTITAL  

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

ACCESS DENIED

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.